S. H. Aghaee-Bakhtiari

Integrated computational framework for drug repurposing in metastatic prostate cancer using transcriptomic meta-analysis, machine learning, and molecular modeling.

CDK1 was identified as a promising therapeutic target, and Tucatinib emerged as the most promising repurposing candidate, warranting further clinical validation.